CRDFCardiff Oncology, Inc.

$139M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$386,000+7.5% YoY

Gross Profit

$386,000100.0% margin

Operating Income

-$40M-10337.3% margin

Net Income

-$39M-10026.9% margin

EPS (Diluted)

$-0.89

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$35M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$116M

Total Liabilities

$10M

Stockholders' Equity

$106M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$386,000	$359,000	+7.5%
Gross Profit	$386,000	$359,000	+7.5%
Operating Income	-$40M	-$29M	-38.3%
Net Income	-$39M	-$28M	-36.8%

CRDF FY 2022 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena